Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Oncology

Why Preserve Fertility Before Osteosarcoma Treatment?

At a Glance

Because osteosarcoma chemotherapy can temporarily or permanently affect fertility, patients and families should discuss preservation before treatment begins. Options vary by age, puberty, anatomy, and available time, and cancer treatment should never be delayed without the oncology team's approval.

In this answer

4 sections

01

How Treatment Affects Fertility

02

Options for Fertility Preservation

03

Sexual Health and Contraception During Treatment

04

What to Do Now

When you or your child is diagnosed with osteosarcoma, the immediate focus is naturally on treating the cancer. However, it is crucial to discuss fertility preservation before beginning treatment because the chemotherapy used for osteosarcoma carries a meaningful but variable risk of temporarily or permanently affecting the reproductive organs [1][2]. Having this conversation early gives you the chance to understand your options, though you should never delay or stop cancer treatment without your oncology team’s approval [3]. Choosing not to pursue preservation is also a valid personal decision; the goal is simply to ensure you are fully informed [3].

How Treatment Affects Fertility

The standard chemotherapy for osteosarcoma is MAP (methotrexate, doxorubicin, and cisplatin) [4]. The risk to future fertility varies widely depending on the specific drugs, cumulative doses, the patient’s age, and their baseline fertility [5]. Other treatments, such as surgery near the pelvis, radiation, or additional drugs like ifosfamide, can also increase this risk [6][1].

  • Cisplatin is known for its potential to cause gonadal injury (damage to the reproductive organs) [7]. In people who produce sperm, it can damage the cells responsible for spermatogenesis [7]. In people with ovaries, it can cause the loss of ovarian follicles (the small sacs inside the ovaries that hold eggs) [8].
  • Doxorubicin has been associated with abnormal markers of ovarian reserve, such as AMH (Anti-Müllerian Hormone) [9]. While these markers estimate the remaining supply of eggs, they do not directly predict whether someone will be able to conceive in the future [10].
  • Methotrexate is not generally considered a major gonadotoxin at the doses used for osteosarcoma, but it is part of the overall regimen [11][5].

Because of these medications, treatment can lead to azoospermia (an absence of sperm in semen) or premature ovarian insufficiency (loss of normal ovarian hormone function before age 40) [12]. While these conditions are sometimes temporary and recovery can occur, the risk of permanent infertility is real and individualized counseling is essential [5][13].

Options for Fertility Preservation

Preservation should ideally be arranged before treatment begins. The right option depends on pubertal status, available time, and anatomy [1]. It is important to note that no method guarantees a future pregnancy, and using frozen eggs, embryos, or tissue will later require assisted reproductive technology (such as IVF) [14].

Options for People Who Produce Sperm

  • Sperm Banking: For adolescents and young men who have gone through puberty and can ejaculate, freezing sperm is the most established method [15]. This requires one or more semen samples and can usually be completed in a few days without delaying chemotherapy [15][3].
  • Testicular Tissue Freezing: For prepubertal boys who do not yet produce sperm, freezing testicular tissue is an experimental/investigational option [3][16]. There is currently no routinely available clinical pathway to use this tissue to achieve a live birth, and availability depends on specific research centers [3].

Options for People with Ovaries

  • Egg or Embryo Freezing: For post-pubertal females, freezing unfertilized eggs or fertilized embryos is standard practice [1][2]. This requires medications to stimulate the ovaries, taking roughly two weeks [16]. Doctors can often use “random-start” stimulation to reduce delays, but your oncology team must confirm if it is safe to wait this long [16][17].
  • Ovarian Tissue Freezing: For prepubertal girls, or when there is no time for ovarian stimulation, freezing ovarian tissue is an established option [18]. While it avoids the two-week stimulation period, it requires surgery and anesthesia, which means it still requires careful coordination with the oncology team to avoid unsafe delays [18][2].

Sexual Health and Contraception During Treatment

It is very important to avoid pregnancy during chemotherapy, as the medications can severely harm a developing fetus [19][20]. Ask your oncology team which forms of contraception are safe and effective for you during treatment, and how long you should continue using them after treatment ends [19][21].

What to Do Now

  • Ask for an urgent referral to a reproductive endocrinologist or an oncofertility specialist (a fertility doctor who works specifically with people receiving cancer treatment) [22][23].
  • Discuss your full treatment plan with both your oncologist and fertility specialist to understand your specific risks [1].
  • If treatment has already started: Do not panic. Contact your oncology team and a fertility specialist anyway. Fertility can sometimes recover, and you can still undergo post-treatment assessment (like semen analysis or hormone testing) and discuss future family-building options after treatment is finished [24][5].

Common questions in this guide

Why should fertility be discussed before osteosarcoma chemotherapy?
Osteosarcoma chemotherapy can temporarily or permanently affect the reproductive organs, especially when cisplatin is part of treatment. Discussing fertility early allows time to consider preservation options, but cancer treatment should never be delayed without approval from the oncology team.
Can MAP chemotherapy affect future fertility?
MAP chemotherapy combines methotrexate, doxorubicin, and cisplatin, and its effect on fertility varies by dose, age, and baseline fertility. Cisplatin can damage sperm-producing cells and ovarian follicles, while methotrexate is generally not considered a major fertility toxin at the doses used for osteosarcoma.
What fertility preservation options are available before osteosarcoma treatment?
People who produce sperm and have gone through puberty may be able to freeze sperm. People with ovaries who have gone through puberty may consider freezing eggs or embryos, while ovarian tissue freezing may be an option for younger patients or when there is little time. Testicular tissue freezing for prepubertal boys remains investigational.
How much time do fertility preservation procedures take before chemotherapy?
Sperm banking can usually be completed within a few days. Egg or embryo freezing generally takes about two weeks, although a random-start approach may reduce delays, while ovarian tissue freezing requires surgery and anesthesia. The oncology and fertility teams must coordinate timing so preservation does not create an unsafe delay in cancer treatment.
What should I do if osteosarcoma treatment has already started?
Contact the oncology team and a fertility specialist even if treatment has begun. Fertility may recover in some people, and semen analysis or hormone testing after treatment can help assess reproductive function and guide future family-building options.
Is pregnancy safe during osteosarcoma chemotherapy?
Pregnancy should be avoided during chemotherapy because these medicines can seriously harm a developing fetus. Ask the oncology team which contraception is safe and effective for you and how long to continue using it after treatment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific risks does my full planned treatment (including MAP, any additional drugs, surgery, or radiation) pose to my future fertility?
  2. 2.Can we safely arrange for fertility preservation procedures without compromising or dangerously delaying the start of my cancer treatment?
  3. 3.Can you urgently refer us to a reproductive endocrinologist or oncofertility program with experience in cancer patients?
  4. 4.What are the safe and effective contraceptive options I should use during my chemotherapy, and how long should I use them?
  5. 5.If standard preservation methods are not feasible for my age or pubertal stage, what experimental options or clinical trials are available locally?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Amputation vs Limb Salvage in Osteosarcoma: Which Is Best?Growing Pains or Osteosarcoma? Key Symptoms to KnowHow Does a Poor Huvos Grade Affect Osteosarcoma Prognosis?What Does "Malignant Osteoid" Mean on a Biopsy Report?How Can Osteosarcoma Survivors Cope With Scanxiety?What Are MAP Chemotherapy Side Effects in Osteosarcoma?How Long Does an Osteosarcoma Diagnosis Usually Take?How Often Are Osteosarcoma Follow-Up Scans Needed?Did My Child Inherit an Osteosarcoma Gene Mutation?What Are the Main Types of Osteosarcoma in Children?How Common Is Osteosarcoma? Incidence and SurvivalOsteosarcoma Lung Relapse: What Are the Treatments?What Do Osteosarcoma Surgical Margins R0, R1, and R2 Mean?Osteosarcoma vs Ewing Sarcoma: What’s the Difference?How Are Heart and Hearing Protected in Osteosarcoma Chemo?What Should Parents Ask an Osteosarcoma Specialist?What Are Skip Metastases? Whole-Bone MRI in OsteosarcomaWhat Should I Bring to a Sarcoma Consultation Appointment?Why Should a Sarcoma Team Plan an Osteosarcoma Biopsy?

References

References (24)
  1. 1

    What should be done in terms of fertility preservation for patients with cancer? The French 2021 guidelines.

    Rives N, Courbière B, Almont T, et al.

    European journal of cancer (Oxford, England : 1990) 2022; (173()):146-166 doi:10.1016/j.ejca.2022.05.013.

    PMID: 35932626
  2. 2

    Fertility Preservation in People With Cancer: ASCO Guideline Update.

    Su HI, Lacchetti C, Letourneau J, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(12)):1488-1515 doi:10.1200/JCO-24-02782.

    PMID: 40106739
  3. 3

    Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update.

    Oktay K, Harvey BE, Partridge AH, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(19)):1994-2001 doi:10.1200/JCO.2018.78.1914.

    PMID: 29620997
  4. 4

    Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.

    Marina NM, Smeland S, Bielack SS, et al.

    The Lancet. Oncology 2016; (17(10)):1396-1408 doi:10.1016/S1470-2045(16)30214-5.

    PMID: 27569442
  5. 5

    A Systematic Review of the Gonadotoxicity of Osteosarcoma and Ewing's Sarcoma Chemotherapies in Postpubertal Females and Males.

    Weidlinger S, Graber S, Bratschi I, et al.

    Journal of adolescent and young adult oncology 2024; (13(4)):597-606 doi:10.1089/jayao.2023.0185.

    PMID: 38629685
  6. 6

    Oncofertility outcomes in early-onset patients with non-breast solid malignancies: a systematic review.

    Shirron N, Boutros A, Waldhorn I, et al.

    EClinicalMedicine 2026; (96()):103979 doi:10.1016/j.eclinm.2026.103979.

    PMID: 42306492
  7. 7

    Extracellular vesicles therapy alleviates cisplatin-ınduced testicular tissue toxicity in a rat model.

    Tozak Yıldız H, Kalkan KT, Baydilli N, et al.

    PloS one 2025; (20(5)):e0314093 doi:10.1371/journal.pone.0314093.

    PMID: 40315228
  8. 8

    Ovarian damage from chemotherapy and current approaches to its protection.

    Spears N, Lopes F, Stefansdottir A, et al.

    Human reproduction update 2019; (25(6)):673-693 doi:10.1093/humupd/dmz027.

    PMID: 31600388
  9. 9

    Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve.

    van den Berg MH, Overbeek A, Lambalk CB, et al.

    Human reproduction (Oxford, England) 2018; (33(8)):1474-1488 doi:10.1093/humrep/dey229.

    PMID: 29982673
  10. 10

    Early Detection of Ovarian Dysfunction by Anti-Mullerian Hormone in Adolescent and Young Adult-Aged Survivors of Childhood Cancer.

    George SA, Williamson Lewis R, Schirmer DA, et al.

    Journal of adolescent and young adult oncology 2019; (8(1)):18-25 doi:10.1089/jayao.2018.0080.

    PMID: 30281375
  11. 11

    Effect of single agent high-dose methotrexate-related acute kidney injury on length of hospitalization and relative dose intensity in adult patients with central nervous system lymphoma.

    Steward JS, Bullard HM, O'Rourke TJ, et al.

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2017; (23(7)):496-501 doi:10.1177/1078155216665244.

    PMID: 27543094
  12. 12

    Anticancer treatment and fertility: Effect of therapeutic modalities on reproductive system and functions.

    Vassilakopoulou M, Boostandoost E, Papaxoinis G, et al.

    Critical reviews in oncology/hematology 2016; (97()):328-34.

    PMID: 26481950
  13. 13

    Fertility assessment and treatment in adolescent and young adult cancer survivors.

    Moravek MB, Pavone ME, Burns K, et al.

    Pediatric blood & cancer 2023; (70 Suppl 5()):e28854 doi:10.1002/pbc.28854.

    PMID: 37381152
  14. 14

    A comparison of fertility preservation outcomes in patients who froze oocytes, embryos, or ovarian tissue for medically indicated circumstances: a systematic review and meta-analysis.

    Ní Dhonnabháin B, Elfaki N, Fraser K, et al.

    Fertility and sterility 2022; (117(6)):1266-1276 doi:10.1016/j.fertnstert.2022.03.004.

    PMID: 35459522
  15. 15

    Fertility preservation in male adolescents with cancer (2011-2020): A retrospective study in China.

    Liu S, Wang Q, Zhu W, et al.

    Cancer medicine 2024; (13(11)):e7354 doi:10.1002/cam4.7354.

    PMID: 38872364
  16. 16

    Clinical practice guideline for female fertility preservation.

    Sun N, Ding H, Cai L, et al.

    Frontiers in medicine 2025; (12()):1730617 doi:10.3389/fmed.2025.1730617.

    PMID: 41705155
  17. 17

    FERTILITY PRESERVATION IN YOUNG WOMEN WITH EARLY-STAGE BREAST CANCER.

    Vuković P, Kasum M, Raguž J, et al.

    Acta clinica Croatica 2019; (58(1)):147-156 doi:10.20471/acc.2019.58.01.19.

    PMID: 31363337
  18. 18

    Importance of ovarian tissue cryopreservation in fertility preservation and anti-aging treatment.

    Vuković P, Kasum M, Orešković D, et al.

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2019; (35(11)):919-923 doi:10.1080/09513590.2019.1611763.

    PMID: 31185756
  19. 19

    Reproductive Function and Outcomes in Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Review.

    van Dorp W, Haupt R, Anderson RA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(21)):2169-2180 doi:10.1200/JCO.2017.76.3441.

    PMID: 29874135
  20. 20

    ACOG Committee Opinion No. 747: Gynecologic Issues in Children and Adolescent Cancer Patients and Survivors.

    Obstetrics and gynecology 2018; (132(2)):e67-e77 doi:10.1097/AOG.0000000000002763.

    PMID: 30045213
  21. 21

    Female cancer survivors: sexual function, psychological distress, and remaining fertility.

    Reiser E, Böttcher B, Ossig C, et al.

    Journal of assisted reproduction and genetics 2024; (41(4)):1057-1065 doi:10.1007/s10815-024-03051-7.

    PMID: 38381389
  22. 22

    Low Anti-Müllerian Hormone in Pediatric Cancer Survivors in the Early Years after Gonadotoxic Therapy.

    Elchuri SV, Patterson BC, Brown M, et al.

    Journal of pediatric and adolescent gynecology 2016; (29(4)):393-9.

    PMID: 26924632
  23. 23

    Controlled ovarian stimulation for oocyte preservation in childhood cancer survivors who have undergone chemotherapy.

    Shapira M, Meirow D, Raved D, et al.

    Human reproduction open 2025; (2025(2)):hoaf023 doi:10.1093/hropen/hoaf023.

    PMID: 40453331
  24. 24

    Long Term Reproductive Health Outcomes in Women Treated for Osteosarcoma During Childhood: A Systematic Review.

    Blyth U, Alwis S, Oo EW, et al.

    Journal of pediatric and adolescent gynecology 2026; (39(3)):426-433 doi:10.1016/j.jpag.2025.11.006.

    PMID: 41248732

This page is for educational purposes about fertility preservation during osteosarcoma treatment and does not constitute medical advice. Your oncology and fertility teams should tailor timing, contraception, and preservation choices to your situation.

Get notified when new evidence is published on Osteosarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.